Explant culture of sarcoma patients' tissue.
Human sarcomas comprise a heterogeneous group of rare tumors that affect soft tissues and bone. Due to the scarcity and heterogeneity of these diseases, patient-derived cells that can be used for preclinical research are limited. In this study, we investigated whether the tissue explant technique can be used to obtain sarcoma cell lines from fresh as well as viable frozen tissue obtained from 8 out of 12 soft tissue and 9 out of 13 bone tumor entities as defined by the World Health Organization. The success rate, defined as the percent of samples that yielded sufficient numbers of outgrowing cells to be frozen, and the time to freeze were determined for a total of 734 sarcoma tissue specimens. In 552 cases (75%) enough cells were obtained to be frozen at early passage. Success rates were higher in bone tumors (82%) compared with soft tissue tumors (68%), and the mean time to freezing was lower in bone tumors (65 days) compared with soft tissue tumors (84 days). Overall, from 40% of the tissues cells could be frozen at early passage within <2 month after tissue removal. Comparable results as with fresh tissue were obtained after explant of viable frozen patient-derived material. In a selected number of bone and soft tissue sarcoma entities, conventional karyotyping and/or FISH (fluorescence in situ hybridization) analysis revealed a high amount (>60%) of abnormal cells in 41% of analyzed samples, especially in bone sarcomas (osteosarcoma and Ewing sarcoma). In conclusion, the explant technique is well suited to establish patient-derived cell lines for a large majority of bone and soft tissue sarcoma entities with adequate speed. This procedure thus opens the possibility for molecular analysis and drug testing for therapeutic decision making even during patient treatment.
Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Zurich, Switzerland.
Roman
R
Muff
Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Zurich, Switzerland.
Sander M
SM
Botter
Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Zurich, Switzerland.
Knut
K
Husmann
Oncology Laboratory, University Children's Hospital Zurich, Zurich, Switzerland.
Joelle
J
Tchinda
Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Zurich, Switzerland.
Philomina
P
Selvam
Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Zurich, Switzerland.
Franziska
F
Seeli-Maduz
Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Zurich, Switzerland.
Bruno
B
Fuchs
D001859:Bone Neoplasms / Q000145:classification / Q000235:genetics / Q000473:pathology*; D002148:Calmodulin-Binding Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D015925:Cryopreservation; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D008297:Male; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics; D034802:RNA-Binding Protein EWS; D016601:RNA-Binding Proteins / Q000235:genetics; D012509:Sarcoma / Q000145:classification / Q000235:genetics / Q000473:pathology*; D012983:Soft Tissue Neoplasms / Q000145:classification / Q000235:genetics / Q000473:pathology*; D046509:Tissue Culture Techniques / Q000379:methods*
D002148:Calmodulin-Binding Proteins; C500986:EWSR1 protein, human; D034802:RNA-Binding Protein EWS; D016601:RNA-Binding Proteins; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2